Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
H. Lee Moffitt Cancer Center and Research Institute National Cancer Institute (NCI) |
---|---|
Information provided by: | H. Lee Moffitt Cancer Center and Research Institute |
ClinicalTrials.gov Identifier: | NCT00325416 |
The purpose of this research study is to determine the safest dose of topotecan when given in a high dose before a stem cell transplant; topotecan will be given with melphalan. The stem cells being transplanted are cells found in the bone marrow and blood that are responsible for making red blood cells, white blood cells, and platelets. The stem cells are collected by a process called leukapheresis and will be frozen for later use. After receiving the chemotherapy drugs, the stem cells will be thawed and given like a blood transfusion. This is called autologous stem cell transplant or rescue.
The study doctors will be measuring how well the disease responds to the drugs as well as any side effects. During the course of this study, blood and bone marrow samples will be obtained to measure levels of the chemotherapy drugs as well as levels of certain enzymes (proteins). The cancer center will continue to collect information about the subject's disease and its treatment for the rest of their life.
Condition | Intervention | Phase |
---|---|---|
Multiple Myeloma |
Drug: melphalan Drug: topotecan Procedure: Bone Marrow Transplant |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Study of Intensive-Dose Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma. |
Estimated Enrollment: | 190 |
Study Start Date: | November 2001 |
Estimated Study Completion Date: | May 2010 |
Estimated Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
The purpose of this research study is to determine the safest dose of topotecan (a chemotherapy drug) when given in a high dose before a stem cell transplant. Topotecan will be given with melphalan, another chemotherapy drug. The stem cells being transplanted are cells found in the bone marrow and blood that are responsible for making red blood cells, white blood cells, and platelets. The stem cells are collected by a process called leukapheresis. After the stem cells are collected, they will be frozen. After the subject receive the chemotherapy drugs mentioned above, the stem cells will be thawed and given like a blood transfusion. This is called autologous stem cell transplant or rescue.
The study doctors will be measuring how well the disease responds to the drugs as well as any side effects to the drugs. During the course of this study, blood and bone marrow samples will be obtained to measure levels of the chemotherapy drugs as well as levels of certain enzymes (proteins). The staff of the Blood and Marrow Transplant program will continue to collect information about the subject's disease and its treatment for the rest of their life.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Christine Simonelli, RN | 813-745-1822 | christine.simonelli@moffitt.org |
United States, Florida | |
H. Lee Moffitt Cancer Center & Research Insitute | Recruiting |
Tampa, Florida, United States, 33612 | |
Contact: Daniel M Sullivan, MD 813-979-3878 sullivad@offitt.usf.edu | |
Contact: Christine McIsaac, RN 813-745-1822 MCISAACE@MOFFITT.USF.EDU | |
Principal Investigator: Daniel M Sullivan, MD | |
Sub-Investigator: Melissa Alsina, MD | |
Sub-Investigator: William S Dalton, PhD, MD | |
Sub-Investigator: Teresa Field, PhD, MD | |
Sub-Investigator: William E Janssen, PhD | |
Sub-Investigator: Janelle Perkins, PharmD | |
Sub-Investigator: Hussain Saba, MD | |
Sub-Investigator: Claudio Anasetti, MD | |
Sub-Investigator: Ernesto Ayala, MD | |
Sub-Investigator: Mohamed Kharfan-Dabaja, MD | |
Sub-Investigator: Richard Lush, Ph.D. | |
Sub-Investigator: Hugo Fernandez, M.D. | |
Sub-Investigator: Jyoti Raychaudhuri, M.D. | |
Sub-Investigator: Lia Perez, M.D. | |
Sub-Investigator: Jose Leonel Ochoa-Bayona, M.D. |
Principal Investigator: | Daniel M Sullivan, MD | H. Lee Moffitt Cancer Center and Research Institute |
Responsible Party: | H. Lee Moffitt Cance Center ( Daniel Sullivan, MD ) |
Study ID Numbers: | MCC-12733 |
Study First Received: | May 11, 2006 |
Last Updated: | October 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00325416 |
Health Authority: | United States: Food and Drug Administration |
melphalan topotecan topoisomerase bone marrow transplant drug sequence |
Melphalan Immunoproliferative Disorders Blood Protein Disorders Hematologic Diseases Blood Coagulation Disorders Vascular Diseases Paraproteinemias |
Hemostatic Disorders Multiple Myeloma Hemorrhagic Disorders Multiple myeloma Topotecan Lymphoproliferative Disorders Neoplasms, Plasma Cell |
Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Immune System Diseases Immunologic Factors Antineoplastic Agents Physiological Effects of Drugs Enzyme Inhibitors Immunosuppressive Agents |
Pharmacologic Actions Neoplasms Therapeutic Uses Myeloablative Agonists Cardiovascular Diseases Antineoplastic Agents, Alkylating Alkylating Agents |